The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

NCT04937673 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Thoracic Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Camrelizumab+Albumin bound paclitaxel+Cisplatin
DRUG: Camrelizumab+ Paclitaxel+ Cisplatin

Sponsor

Peking University